MALT1 and glioblastoma: Finally, an increasing number of publications support a role for aberrant MALT1 signaling in the development of non-lymphoid cancers, such as glioblastoma (127), breast cancer (18, 128, 129), melanoma (130), lung cancer (18), and various other carcinomas (1, 131, 132).